Rich Steffens
Contributor since: 2008
Latest Articles
Emerging Biotech Takes Aim At Preventing Recurrent Breast Cancer
A Fact Based Analysis Of Galena's NeuVax
A New Look At Galena's NeuVax While Lowering Analyst's Raised Red Flags
Generex's Antigen Express Makes Progress In Early Stage Breast Cancer
Filling an Unmet Need: A Look at Generex and RXI Pharma's Breast Cancer Vaccines
Generex to Spin Off Antigen Express to Unlock True Value
Generex Taps Former Eli Lilly Medical Director to Strengthen Clinical and Regulatory Efforts
Talking Big Pharma, Vaccines and Baseball With Generex's Dr. Eric von Hofe
Why I Am Voting for Generex's Reverse Stock Split
Generex 's Acquisition Into the Direct to Consumer Diabetes Market Provides Synergistic Value
Analyzing Generex and Throwing Darts With Pfizer's Craig Eagle
Good News for Generex: Positive Data on Oral Insulin Coming in September
Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy
Sorting Out The Street's Misinformation on Generex
Byetta LARS: How the FDA's Analysis Paralysis May Aid Amylin
Large Pharma and Small Biotech Deals Expected to Increase in 2010
Oral-lyn vs. Afresa: How Generex Will Beat Mannkind
A N.I.C.E. Development for Generex Oral-lyn in the U.K.
Genentech and Generex: New HER2/neu Research
Four Drug Companies Vying for Diabetes Patients
Generex Biotechnology and the USMCI: Armed with Antigens in the War Against Breast Cancer
ADA's 68th Scientific Sessions: A New Look at Insulin Therapy
Generex Biotech's Oral-lyn Granted Special Access Authorization by Health Canada
Oral Insulin: Balancing Safety with Efficacy
Generex Biotechnology: Oral-lyn Buccal Insulin Takes Center Stage